Developing a vaccine for Chikungunya
Investment Q2 2019
Themis’ lead program is a vaccine for Chikungunya, a debilitating disease with global outbreak potential, developed using its measles vaccine vector platform. The vaccine candidate, MV-CHIK, is Phase 3-ready with the pivotal global Phase 3 trial initiation expected in the next few months. Themis recently announced a partnership with MSD to develop undisclosed vaccine candidates. In 2018, the company initiated its immuno-oncology portfolio with the first therapeutic candidate to enter clinical studies this year.